期刊文献+

^(89)Sr照射对乳腺癌MCF-7细胞分泌sFas、sFasL的影响 被引量:1

Effects of ^(89)strontium irradiation on sFas and sFasL excreted from breast cancer MCF-7 cells
下载PDF
导出
摘要 目的探讨89Sr照射对乳腺癌MCF-7细胞分泌sFas、sFasL的影响。方法采用不同浓度89Sr照射乳腺癌MCF-7细胞,培养24 h后,用酶联免疫吸附试验检测细胞培养上清液中的sFas、sFasL水平。结果乳腺癌MCF-7细胞分泌sFas、sFasL;89Sr照射可明显抑制MCF-7细胞增殖,随着89Sr浓度升高,其sFas、sFasL水平逐渐下降,89Sr不同浓度间的sFas、sFasL水平两两比较,P均<0.05。结论89Sr可诱导乳腺癌MCF-F细胞凋亡,89Sr照射能有效降低MCF-7细胞分泌sFas、sFasL的水平;sFas的动态变化可能与乳腺癌细胞发生、发展的病理生理过程有关。 Objective To investigate the effects of 89strontium (89Sr) irradiation on the levels of sFas and sFasL excreted from breast cancer MCF-7 cells. Methods MCF-7 cells were irradiated by different concentrations of 89Sr and cultured for 2d h. Enzyme-linked immunosorbent assay(ELISA) was applied to detect the levels of sFas and sFasL in the cell culture supernate. Results The breast cancer MCF-7 cells excreted sFas and sFasL. 89Sr irradiation had significant inhibitory effect on the proliferation of MCF-7 cells. The levels of sFas and sFasL decreased when the concentrations of 89sr increased. The levels of sFas and sFasl were significantly different between different concentrations of 89Sr irradiation ( all P 〈 0. 05). Conclusions Apoptosis of breast cancer MCF-7cells can be induced by 89Sr. The levels of sFas and sFasL excreted from MCF-7 decreased when irradiated by 89Sr. The dynamic changes in levels of sFas and sFasL may be associat- ed with the occurrence, development of breast cancer pathogenesis.
出处 《山东医药》 CAS 2013年第33期15-16,19,共3页 Shandong Medical Journal
基金 温州市科技局科研项目(Y200801)
关键词 乳腺肿瘤 MCF-7细胞 89Sr 细胞凋亡相关蛋白 breast neoplasms MCF-7 cells 89 strontium apoptosis-related protein
  • 相关文献

参考文献12

  • 1Kushlinskii NE,Britvin TA,Abbagova SG,et al.Soluble Fag antigen in the serum of patients with colon cancer[J].Bull Exp Biol Med,2001,131 (4):361-363.
  • 2Jiang J,Ulbright TM,Zhang S,et al.Fag and Fag ligand exptession is elevated in prostatic in traepith-elial neoplagia and prostatic adenocarcinoma[J].Cancer,2002,95 (2),296-300.
  • 3Hefler L,Mayerhofer K,Nardi A,et al.Serum soluble Fas levels in ovarian cancer[J].Obstet Gynecol,2000,96(1):65-69.
  • 4Nomomura N,Nishimura K,Ono Y,et al.Soluble Fas in serum from patients with renal cell carcinoma[J].Urology,2000,55(2):151-155.
  • 5韩苏夏,朱青,李明众.Fas/FasL及其与肿瘤的关系[J].西安医科大学学报,2000,21(4):397-398. 被引量:10
  • 6Sheen-Chen SM,Chen HS,Eng HL,et al.Circulating soluble fas in patients with breast cancer[J].World J Surg,2003,27(1):10-13.
  • 7Liu QY,Rubin MA,Omene C,et al.Fas ligand is constitutively secreted by prostate cancer cells in vitro[J].Clin Cancer Res,1998,4(2):1803-1811.
  • 8苏逢锡,贾渭娟,陈积圣,宋尔卫.乳腺癌细胞可溶性FasL分泌及其对淋巴细胞凋亡的诱导[J].肿瘤,2000,20(4):310-312. 被引量:3
  • 9Blake GM,Zivanovic MA,McEwan A J,et al.Sr-89 therapy:Strontium Kinetics in disseminated carcinoma of the prostate[J].Eur J Nucl MED,1986,12(9):447-454.
  • 10贾东升,杨全成,王彤,郑杰,车梓.唑来膦酸联合放射性核素^(89)Sr静脉应用治疗前列腺癌转移性骨痛疗效观察[J].山东医药,2010,50(46):50-51. 被引量:3

二级参考文献23

  • 1Pons F, Herrgnz R, Carcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast caner [J]. Eur J Nucl Med, 1997,24(10) :1210-1214.
  • 2中华人民共和国卫生部医政司.核医学诊断和治疗规范[M].北京:科学技术出版社.1997:292-295.
  • 3Serafini AN. Therapy of metastatic bone pain [ J ]. J Nucl Med, 2001,42 (6) : 895-906.
  • 4Hillegonds DJ, Franklin S, Shelton DK, et al. The management of painful bone metastases with an emphasis on radionuelide therapy [J]. J Natl Med Assoc, 2007,99(7) :785-794.
  • 5Kraeber-Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride : Efficacy in relation to the degree of bone involvement [ J ]. Eur J Nuel Med ,2000,27 (10) : 1487-1493.
  • 6Zoner N, Keck AV, Pecherstoffer M. Comparative tolerability of drug therapies for hypercalcacmia of malignancy [ J ]. Drug Saf, 1999,21 (5) :389-406.
  • 7Lee CK, Aeppli DM, Unger J, et al. Strontium-89 chloride ( Metastron) for palliative treatment of bony metastases[J]. Am J Clin Oncol, 1996,19(2) :102-107.
  • 8Lam MG, Dahmane A, Stevens WH, et al. Combined use of zoledrenic acid and ^153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases[J]. Eur J Nucl Mol Imaging, 2008, 35(4) :756-765.
  • 9Liu Q Y,Clin Cancer Res,1998年,4卷,1803页
  • 10中华人民共和国卫生部医政司,核医学诊断与治疗规范,1997年,293页

共引文献66

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部